---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-337646"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-12-31T23:59:59+00:00"
generated_at: "2026-05-16T11:55:03.736196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership

## Summary
- Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.
- BioAtla retains 65% ownership of Oz-V across all solid tumor indications after transaction.
- Proceeds fund Phase 3 trial for Oz-V in 2L+ OPSCC; enrollment expected to begin early 2026.
- Related-party transaction: Chairman/CEO Dr. Jay Short and spouse are managers of Inversagen entities.

## SEC filing metadata
- accession: 0001193125-25-337646
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-12-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/0001193125-25-337646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/d20340d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-337646
- JSON: https://secwatch.observer/filing/0001193125-25-337646.json
- Plain text: https://secwatch.observer/filing/0001193125-25-337646.txt

## Key facts
- Material Agreements
  BioAtla, Inc. entered into Investment Agreement with Inversagen AI, LLC and Alliance International Resources Corp. valued at aggregate $40 million (effective 2025-12-30).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Inversagen AI, LLC and Alliance International Resources Corp.
  - Value: aggregate $40 million
  - Effective: 2025-12-30
  source text: On December 30, 2025, BioAtla, Inc. (“the Company” or “BioAtla”) entered into an Investment Agreement (the “Investment Agreement”) with Inversagen AI, LLC, a Delaware limited liability company (“Inversagen AI”), and Alliance International Resources Corp., a Nevada corporation (“AIRC”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/0001193125-25-337646-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.